Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jan 20;10(3):550–557. doi: 10.1158/1535-7163.MCT-10-0571

Figure 2.

Figure 2

Expression of EGFR, P63 and P73 in CRL2335 and MDA-MB-468 TNBC cells and CRL8799 normal breast cancer cells treated with cisplatin, TRAIL or cisplatin plus TRAIL (10 μg/ml, 10 ng/ml and 10 μg/ml+10 ng/ml, respectively) for 24 h. Whole cell extracts were prepared and analyzed for EGFR, P63, P73 by Western blotting. Equal protein loading was compared with that of GAPDH.